
Teva
Global Generic Pharmaceuticals Company.
Enterprise value
$34.7b
Share price
$16.76 TEVA
Company register number
26918757
Recent deals
loading funding rounds…
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | (1 %) | (5 %) | (6 %) | 6 % | 4 % | 3 % | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 28 % | 29 % | 28 % | 27 % | 26 % | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (24 %) | 3 % | (16 %) | (4 %) | (10 %) | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 6 % | 6 % | 6 % | 6 % | 6 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.

exited

exited

ACQUISITION by Roche Dec 2017

ACQUISITION by Teva Jul 2015

ACQUISITION by Biozone Pharmaceuticals Jan 2014

ACQUISITION by Teva May 2011

ACQUISITION by Sosei Group Feb 2015

ACQUISITION by Teva Mar 2015

exited